Immunotherapy Provides Durable Disease Control In HRP Ovarian Cancer
MedPage Today (12/1, Bankhead) reported, “A novel immunotherapy provided durable disease control in homologous repair proficient (HRP) ovarian cancer, subgroup data from a small randomized trial showed.” After three years of surveillance, the “median overall survival (OS) had yet to be reached in patients who received gemogenovatucel-T (Vigil), but appeared to exceed 41 months, as compared with […]